The evaluation period used to determine the efficacy of chronic hepatitis C treatments has been reduced in Korea.

The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) revised the 'Clinical Trial Evaluation Guidelines for Chronic Hepatitis C Treatments' on June 29 to align Korea’s clinical trial efficacy evaluation standards with the international standards and reflect the standard treatment method for chronic hepatitis C treatments.

The main revisions included ▲changing the evaluation period of major efficacy evaluation indices, ▲setting toxicity test exemption standards for combination drugs, and ▲reflecting the latest chronic hepatitis C standard of care to the guidelines.